CVS Pharmacy, Inc. v. Lavin

951 F.3d 50
Court of Appeals for the First Circuit·Decided February 28, 2020·No. 19-1638P·Published·Cited by 16 cases

Opinion

United States Court of Appeals For the First Circuit

No. 19-1638 CVS PHARMACY, INC.,

Plaintiff, Appellee,

v.

JOHN LAVIN,

Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF RHODE ISLAND

[Hon. John J. McConnell, Jr., U.S. District Judge]

Before

Lynch, Selya, and Lipez,

Circuit Judges.

John J. Cotter, with whom Jennifer J. Nagle and K&L Gates LLP were on brief, for appellant.

Michael L. Rosen, with whom Richard G. Baldwin, Allison L.

Anderson, and Foley Hoag LLP were on brief, for appellee.

February 28, 2020

LIPEZ, Circuit Judge. After working for nearly three decades at plaintiff-appellee CVS Pharmacy, Inc., defendant- appellant John Lavin accepted a new position at PillPack LLC, a direct competitor of CVS. But Lavin never actually started that job. After obtaining information about Lavin's new role, CVS sued Lavin, seeking to enforce a covenant not to compete (the "covenant" or the "Agreement") included in a Restrictive Covenant Agreement ("RCA") that Lavin signed in 2017. Finding that Lavin's new position would violate the covenant and concluding that the covenant was reasonable, the district court entered a preliminary injunction enjoining Lavin from working at PillPack for eighteen months, the duration specified in the covenant. In this interlocutory appeal, Lavin argues that the covenant is not reasonable and that the preliminary injunction, therefore, should not have been granted. Although our reasoning differs somewhat from that of the district court, we affirm the entry of a preliminary injunction enforcing the covenant not to compete.

I.

A. Factual Background1 1. CVS Caremark's Business CVS operates CVS Caremark, one of the country's largest pharmacy benefit managers ("PBMs"). PBMs sell prescription- management services to entities providing prescription-drug coverage to their members. These entities -- known as payers -- include employers, insurance companies, and unions. PBMs negotiate on behalf of payers with pharmacies to secure reimbursement rates for prescription drugs. They also establish pharmacy networks for payers, premised on each payer's individual needs and preferences; furnish an array of administrative services (such as claims adjudication and eligibility determinations); and procure bulk discounts and rebates directly from pharmaceutical manufacturers. For its part, CVS Caremark offers its own mail- order pharmacy services to certain payers as clients.

CVS operates other healthcare-related subsidiaries in addition to CVS Caremark, including a sprawling chain of retail pharmacies. CVS has erected a firewall between CVS Caremark and its retail pharmacy subsidiary. This firewall not only prevents

1 "[W]e credit the undisputed facts presented below and adopt the district court's findings as to controverted matters to the extent they are supported by the record and not clearly erroneous." United Elec., Radio & Mach. Workers of Am. v. 163 Pleasant St. Corp., 960 F.2d 1080, 1083 (1st Cir. 1992).

CVS Caremark's employees from accessing the prices that CVS's retail pharmacies negotiate with other PBMs but also prevents employees of CVS's retail pharmacies from accessing the prices that CVS Caremark negotiates with other retail pharmacies.

2. Lavin's Employment at CVS After his almost three decades at CVS Caremark and its predecessor, Lavin became Senior Vice President for Provider Network Services in 2010. In this role, he oversaw a team of approximately 250 people and was responsible for negotiating pricing contracts with retail pharmacies, auditing pharmacies, and setting up pharmacy networks for payers. He also participated in regular underwriting calls for the contracts that CVS Caremark negotiated with its payer clients. In light of these duties, he became intimately familiar with the prices and terms of CVS Caremark's deals with both retail pharmacies and payers.

Lavin was also involved in certain strategic initiatives undertaken by CVS Caremark. For instance, he assisted with the company's strategy for contracting with mail-in retail pharmacies ("MIRs"), which fill prescriptions by mail. This project included developing strategies about how best to differentiate CVS Caremark's mail-based services from those offered by MIRs. He helped formulate CVS Caremark's strategy for the upcoming contracting cycle and create novel pharmacy reimbursement and pricing models. Each year, he attended several executive committee

meetings that covered an array of topics ranging from revenue and pricing to major client accounts and regulatory impacts.

3. Noncompetition Agreement At four points during his tenure as a senior vice president at CVS Caremark -- in 2011, 2012, 2014, and 2017 -- CVS required Lavin to sign an RCA. Each RCA contained noncompetition, nonsolicitation, and nondisclosure covenants. Each time Lavin signed an RCA, he was awarded CVS stock.

The 2017 RCA, executed in exchange for a stock award worth $157,500, is the centerpiece of this appeal. The covenant not to compete contained therein bars Lavin, for eighteen months after the termination of his employment, from "directly or indirectly . . . engag[ing] in Competition" anywhere in the United States that CVS operates. The covenant in the 2017 RCA defines "Competition" as:

[P]roviding services to a Competitor of the Corporation [CVS] . . . that: (i) are the same or similar in function or purpose to the services I [Lavin] provided to the Corporation at any time during the last two years of my employment by the Corporation; or (ii) will likely result in the disclosure of Confidential Information to a Competitor or the use of Confidential Information on behalf of a Competitor.

"Competitor" is defined, in turn, as:

[A]ny person, corporation or other entity that competes with one or more of the business offerings of the Corporation[.] . . . [T]he Corporation's business offerings include:

(i) pharmacy benefits management ("PBM")

. . .; (ii) retail, which includes the sale of prescription drugs, over-the-counter medications, [and other products and services sold by CVS's retail pharmacies] ("Retail");

(iii) retail health clinics ("MinuteClinic");

(iv) the provision of [various products and services] to long-term care facilities, other healthcare service providers and recipients of services from such facilities ("Long-Term Care"); (v) the provision of prescription infusion drugs and related services ("Infusion"); and (vi) any other business in which [the] Corporation is engaged or imminently will be engaged.

. . . .

The Parties acknowledge that . . . an entity will be considered a Competitor if it provides products or services competitive with the products and services provided by the Corporation within the last two years of my employment.

I agree to this enterprise-wide definition of non-competition which may prevent me from providing services to any of the Corporation's PBM, Retail, MinuteClinic, Long-Term Care and Infusion Competitors or any combination thereof . . . .

This definition of "Competition" and the eighteen-month noncompetition period appear in all four of the RCAs that Lavin signed. However, the definition of "Competitor" expanded over time. The 2011 and 2012 RCAs limited "Competitors" to other companies providing PBM services. The 2014 RCA expanded this definition to include retail pharmacies and health clinics, as well as any other entity that "provides products or services competitive with the products and services provided by the

Corporation within the last two years" of Lavin's employment. By 2017, as stated above, the definition of "Competitor" included companies providing services to long-term care facilities and prescription infusion drugs.

Free access — add to your briefcase to read the full text and ask questions with AI

CVS Pharmacy, Inc. v. Lavin, 951 F.3d 50 (1st Cir. 2020).

951 F.3d 50 (CVS Pharmacy, Inc. v. Lavin) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related